AU2016363719B2 - 1,3,4-thiadiazole compounds and their use in treating cancer - Google Patents

1,3,4-thiadiazole compounds and their use in treating cancer Download PDF

Info

Publication number
AU2016363719B2
AU2016363719B2 AU2016363719A AU2016363719A AU2016363719B2 AU 2016363719 B2 AU2016363719 B2 AU 2016363719B2 AU 2016363719 A AU2016363719 A AU 2016363719A AU 2016363719 A AU2016363719 A AU 2016363719A AU 2016363719 B2 AU2016363719 B2 AU 2016363719B2
Authority
AU
Australia
Prior art keywords
methoxy
pyrrolidin
amino
acetamide
thiadiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016363719A
Other languages
English (en)
Other versions
AU2016363719A1 (en
AU2016363719A8 (en
Inventor
Mark David Charles
Maurice Raymond Verschoyle Finlay
Johannes Wilhelmus Maria Nissink
James Matthew Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
AstraZeneca AB
Original Assignee
Cancer Research Technology Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd, AstraZeneca AB filed Critical Cancer Research Technology Ltd
Publication of AU2016363719A1 publication Critical patent/AU2016363719A1/en
Publication of AU2016363719A8 publication Critical patent/AU2016363719A8/en
Application granted granted Critical
Publication of AU2016363719B2 publication Critical patent/AU2016363719B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2016363719A 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer Ceased AU2016363719B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562260787P 2015-11-30 2015-11-30
US62/260787 2015-11-30
PCT/EP2016/079251 WO2017093300A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (3)

Publication Number Publication Date
AU2016363719A1 AU2016363719A1 (en) 2018-07-05
AU2016363719A8 AU2016363719A8 (en) 2018-07-12
AU2016363719B2 true AU2016363719B2 (en) 2019-11-14

Family

ID=57421876

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016363719A Ceased AU2016363719B2 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Country Status (25)

Country Link
US (1) US9938265B2 (enExample)
EP (1) EP3383871B1 (enExample)
JP (1) JP6873132B2 (enExample)
KR (1) KR20180083412A (enExample)
CN (1) CN108349967B (enExample)
AR (1) AR106876A1 (enExample)
AU (1) AU2016363719B2 (enExample)
BR (1) BR112018010812A2 (enExample)
CA (1) CA3005516C (enExample)
CL (1) CL2018001408A1 (enExample)
CO (1) CO2018006929A2 (enExample)
DK (1) DK3383871T3 (enExample)
DO (1) DOP2018000134A (enExample)
EA (1) EA201891240A1 (enExample)
ES (1) ES2759940T3 (enExample)
IL (1) IL258644A (enExample)
MX (1) MX2018006528A (enExample)
NI (1) NI201800065A (enExample)
PE (1) PE20181450A1 (enExample)
PH (1) PH12018501132A1 (enExample)
SG (1) SG11201803813UA (enExample)
SV (1) SV2018005701A (enExample)
TN (1) TN2018000126A1 (enExample)
TW (1) TW201730188A (enExample)
WO (1) WO2017093300A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201731511A (zh) * 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) * 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
ES2939506T3 (es) 2018-10-16 2023-04-24 Medshine Discovery Inc Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer
WO2025196446A1 (en) * 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015181539A1 (en) * 2014-05-30 2015-12-03 Astrazeneca Ab 1, 3, 4-thiadiazole compounds and their use in treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2295068T3 (es) * 1999-11-24 2008-04-16 MERCK & CO., INC. Gamma-hidroxi-2-(fluoroalquilaminocarbonil)-1-piperazinpentanamidas como inhibidores de la proteasa del vih.
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
AR044688A1 (es) * 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
WO2006053342A2 (en) * 2004-11-12 2006-05-18 Osi Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
MX2011011094A (es) * 2009-04-20 2011-11-04 Hoffmann La Roche Derivados de prolina como inhibidores de catepsina.
CN108785305B (zh) * 2011-11-21 2021-10-29 卡利泰拉生物科技公司 谷氨酰胺酶的杂环抑制剂
HUE056078T2 (hu) * 2012-11-16 2022-01-28 Calithera Biosciences Inc Heterociklusos glutamináz inhibitorok
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
KR20160100407A (ko) * 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
WO2015138902A1 (en) * 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015181539A1 (en) * 2014-05-30 2015-12-03 Astrazeneca Ab 1, 3, 4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
CO2018006929A2 (es) 2018-10-10
ES2759940T3 (es) 2020-05-12
NI201800065A (es) 2018-10-18
MX2018006528A (es) 2019-05-15
EP3383871B1 (en) 2019-09-11
US9938265B2 (en) 2018-04-10
WO2017093300A1 (en) 2017-06-08
SV2018005701A (es) 2018-11-27
AU2016363719A1 (en) 2018-07-05
DOP2018000134A (es) 2018-06-30
DK3383871T3 (da) 2019-12-16
AR106876A1 (es) 2018-02-28
JP2019501134A (ja) 2019-01-17
IL258644A (en) 2018-06-28
JP6873132B2 (ja) 2021-05-19
EP3383871A1 (en) 2018-10-10
CN108349967B (zh) 2022-02-15
AU2016363719A8 (en) 2018-07-12
TN2018000126A1 (en) 2019-10-04
CN108349967A (zh) 2018-07-31
KR20180083412A (ko) 2018-07-20
TW201730188A (zh) 2017-09-01
US20170152254A1 (en) 2017-06-01
EA201891240A1 (ru) 2018-11-30
PH12018501132A1 (en) 2019-01-21
ES2759940T8 (es) 2020-05-20
PE20181450A1 (es) 2018-09-12
CA3005516A1 (en) 2017-06-08
CA3005516C (en) 2024-04-16
CL2018001408A1 (es) 2018-10-12
BR112018010812A2 (pt) 2018-11-27
SG11201803813UA (en) 2018-06-28

Similar Documents

Publication Publication Date Title
US10294221B2 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
US11753405B2 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
AU2016361834B2 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
CA3005516C (en) 1,3,4-thiadiazole compounds and their use in treating cancer
US10577354B2 (en) Bis-pyridazine compounds and their use in treating cancer
HK1260702A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260702B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260707B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260707A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 32 , NO 25 , PAGE(S) 3591 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ASTRAZENECA AB; CANCER RESEARCH TECHNOLOGY LIMITED, APPLICATION NO. 2016363719, UNDER INID (72) CORRECT THE CO-INVENTOR TO WOOD, JAMES MATTHEW

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired